• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.PPAR-α 激动剂非诺贝特对脑缺血急性和短期后果的影响。
J Cereb Blood Flow Metab. 2014 Mar;34(3):542-51. doi: 10.1038/jcbfm.2013.233. Epub 2014 Jan 8.
2
PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia.过氧化物酶体增殖物激活受体α激动剂非诺贝特改善全脑缺血大鼠的学习和记忆缺陷
Mol Neurobiol. 2015 Aug;52(1):601-9. doi: 10.1007/s12035-014-8882-7. Epub 2014 Sep 23.
3
Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.过氧化物酶体增殖物激活受体-α激活可减轻 3-硝基丙酸诱导的大鼠行为和生化改变:可能的神经保护机制。
Eur J Pharmacol. 2012 Jan 5;674(1):33-43. doi: 10.1016/j.ejphar.2011.10.029. Epub 2011 Oct 26.
4
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.单一和联合激活过氧化物酶体增殖物激活受体-α和过氧化物酶体增殖物激活受体-γ对脑缺血再灌注后神经功能结局的影响。
Life Sci. 2020 Jul 1;252:117679. doi: 10.1016/j.lfs.2020.117679. Epub 2020 Apr 20.
5
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.过氧化物酶体增殖物激活受体-α激活作为慢性非诺贝特治疗诱导预防性神经保护的机制。
J Neurosci. 2003 Jul 16;23(15):6264-71. doi: 10.1523/JNEUROSCI.23-15-06264.2003.
6
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.过氧化物酶体增殖物激活受体α和γ激动剂在黑质内注射1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导的帕金森病模型中的神经保护作用
Behav Brain Res. 2014 Nov 1;274:390-9. doi: 10.1016/j.bbr.2014.08.014. Epub 2014 Aug 13.
7
The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment.过氧化物酶体增殖物激活受体(PPAR)α 激动剂非诺贝特可预防分次全脑照射诱导的认知障碍。
Radiat Res. 2014 Jan;181(1):33-44. doi: 10.1667/RR13202.1. Epub 2014 Jan 7.
8
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.过氧化物酶体增殖物激活受体(PPAR)--α 和 γ 激动剂对大鼠口腔运动障碍模型的可能有益作用。
Pharmacol Biochem Behav. 2013 Oct;111:17-23. doi: 10.1016/j.pbb.2013.08.001. Epub 2013 Aug 12.
9
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.非诺贝特,一种过氧化物酶体增殖物激活受体α激动剂,在创伤性脑损伤中发挥神经保护作用。
Neurosci Lett. 2005 Nov 4;388(1):7-12. doi: 10.1016/j.neulet.2005.06.019.
10
Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction.非诺贝特,一种过氧化物酶体增殖物激活受体-α激动剂,可阻断脂肪变性并改变炎症-二恶英相互作用的小鼠模型中的炎症反应。
Chem Biol Interact. 2021 Aug 25;345:109521. doi: 10.1016/j.cbi.2021.109521. Epub 2021 May 27.

引用本文的文献

1
The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation.激肽释放酶原抑制蛋白通过诱导β-淀粉样蛋白斑块积聚和tau蛋白过度磷酸化在连接代谢综合征与认知记忆衰退中的新作用。
Elife. 2025 Aug 5;13:RP99462. doi: 10.7554/eLife.99462.
2
Role of peroxisome proliferator-activated receptor alpha in neurodegenerative diseases and other neurological disorders: Clinical application prospects.过氧化物酶体增殖物激活受体α在神经退行性疾病和其他神经系统疾病中的作用:临床应用前景
Neural Regen Res. 2025 Jun 19. doi: 10.4103/NRR.NRR-D-24-01371.
3
Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation.靶向激活过氧化物酶体增殖物激活受体α(PPARα)可使胶质母细胞瘤细胞对替莫唑胺敏感,并通过抑制组蛋白H3第18位赖氨酸乳酸化(H3K18 lactylation)逆转获得性耐药。
Acta Pharmacol Sin. 2025 Jun 11. doi: 10.1038/s41401-025-01600-z.
4
Epilepsy and autophagy modulators: a therapeutic split.癫痫与自噬调节剂:一种治疗分歧。
Autophagy. 2025 Sep;21(9):1863-1887. doi: 10.1080/15548627.2025.2506292. Epub 2025 May 30.
5
PPARα Genetic Deletion Reveals Global Transcriptional Changes in the Brain and Exacerbates Cerebral Infarction in a Mouse Model of Stroke.过氧化物酶体增殖物激活受体α基因缺失揭示了大脑中的全局转录变化并加重了中风小鼠模型中的脑梗死。
Int J Mol Sci. 2025 Apr 25;26(9):4082. doi: 10.3390/ijms26094082.
6
Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.当前对 PPAR-α 的认识及其与阿尔茨海默病和其他神经精神疾病中神经甾体的关系:治疗策略中的有前途靶点。
Int J Mol Sci. 2024 Jun 28;25(13):7106. doi: 10.3390/ijms25137106.
7
Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.血管内皮功能障碍与脑卒中患者的认知障碍前状态
Biomolecules. 2024 Jun 18;14(6):721. doi: 10.3390/biom14060721.
8
No-reflow after recanalization in ischemic stroke: From pathomechanisms to therapeutic strategies.缺血性脑卒中再通后无复流:从病理机制到治疗策略。
J Cereb Blood Flow Metab. 2024 Jun;44(6):857-880. doi: 10.1177/0271678X241237159. Epub 2024 Feb 29.
9
PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice.过氧化物酶体增殖物激活受体α激动剂非诺贝特通过增强小鼠脂肪酸氧化来预防术后认知功能障碍。
Transl Neurosci. 2023 Nov 15;14(1):20220317. doi: 10.1515/tnsci-2022-0317. eCollection 2023 Jan 1.
10
The synergistic ameliorative activity of peroxisome proliferator-activated receptor-alpha and gamma agonists, fenofibrate and pioglitazone, on hippocampal neurodegeneration in a rat model of insulin resistance.过氧化物酶体增殖物激活受体α和γ激动剂非诺贝特和吡格列酮对胰岛素抵抗大鼠模型海马神经退行性变的协同改善作用。
Ibrain. 2022 Aug 8;8(3):251-263. doi: 10.1002/ibra.12059. eCollection 2022 Fall.

本文引用的文献

1
PPARs: a potential target for a disease-modifying strategy in stroke.过氧化物酶体增殖物激活受体(PPARs):一种用于中风疾病修饰策略的潜在靶点。
Curr Drug Targets. 2013 Jun;14(7):752-67. doi: 10.2174/1389450111314070005.
2
Cerebrovascular lesions induce transient β-amyloid deposition.脑血管病变可导致短暂的β-淀粉样蛋白沉积。
Brain. 2011 Dec;134(Pt 12):3697-707. doi: 10.1093/brain/awr300. Epub 2011 Nov 26.
3
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.核受体PPARγ作为阿尔茨海默病脑血管和脑功能障碍的治疗靶点
Front Aging Neurosci. 2010 May 21;2. doi: 10.3389/fnagi.2010.00021. eCollection 2010.
4
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.痴呆症发病机制中神经退行性和血管因素的重叠。
Acta Neuropathol. 2010 Sep;120(3):287-96. doi: 10.1007/s00401-010-0718-6. Epub 2010 Jul 11.
5
Consideration of the ischaemic basis and treatment of Alzheimer's disease.考虑阿尔茨海默病的缺血基础和治疗。
Folia Neuropathol. 2010;48(1):11-26.
6
Characterization of acute adverse-effect profiles of selected antiepileptic drugs in the grip-strength test in mice.在小鼠握力试验中对选定抗癫痫药物的急性不良反应特征进行描述。
Pharmacol Rep. 2009 Jul-Aug;61(4):737-42. doi: 10.1016/s1734-1140(09)70128-8.
7
Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection.停用非诺贝特治疗部分通过血管保护丧失来消除中风的预防神经保护作用。
Vascul Pharmacol. 2009 Nov-Dec;51(5-6):323-30. doi: 10.1016/j.vph.2009.08.002. Epub 2009 Sep 2.
8
Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.非诺贝特可改善小鼠大脑中动脉闭塞后的脑血流。
J Cereb Blood Flow Metab. 2010 Jan;30(1):70-8. doi: 10.1038/jcbfm.2009.185. Epub 2009 Sep 2.
9
Neurogenesis and angiogenesis within the ipsilateral thalamus with secondary damage after focal cortical infarction in hypertensive rats.高血压大鼠局灶性皮质梗死后同侧丘脑继发性损伤中的神经发生和血管生成
J Cereb Blood Flow Metab. 2009 Sep;29(9):1538-46. doi: 10.1038/jcbfm.2009.76. Epub 2009 Jun 17.
10
Neuronal response of peroxisomal and peroxisome-related proteins to chronic and acute Abeta injury.过氧化物酶体及过氧化物酶体相关蛋白对慢性和急性β淀粉样蛋白损伤的神经元反应。
Curr Alzheimer Res. 2009 Jun;6(3):238-51. doi: 10.2174/156720509788486518.

PPAR-α 激动剂非诺贝特对脑缺血急性和短期后果的影响。

Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.

机构信息

EA 1046-Département de Pharmacologie médicale, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France.

1] EA 1046-Département de Pharmacologie médicale, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France [2] EA 4484-Département de Physiologie, University Lille Nord de France; Université de Lille 2-Faculté de Médecine; Centre Hospitalier Universitaire; Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France.

出版信息

J Cereb Blood Flow Metab. 2014 Mar;34(3):542-51. doi: 10.1038/jcbfm.2013.233. Epub 2014 Jan 8.

DOI:10.1038/jcbfm.2013.233
PMID:24398933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3948136/
Abstract

In stroke, there is an imperative need to develop disease-modifying drugs able to (1) induce neuroprotection and vasculoprotection, (2) modulate recovery and brain plasticity, and (3) limit the short-term motor and cognitive consequences. We hypothesized that fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, could exert a beneficial effect on immediate and short-term poststroke consequences related to its pleiotropic mechanisms. Rats or mice were subjected to focal ischemia to determine the effects of acute treatment by fenofibrate on (i) motor and memory impairment, (2) both cerebral and vascular compartments, (3) inflammation, (4) neurogenesis, and (5) amyloid cascade. We show that fenofibrate administration results in both neuronal and vascular protection and prevents the short-term motor and cognitive poststroke consequences by interaction with several mechanisms. Modulation of PPAR-α generates beneficial effects in the immediate poststroke consequences by mechanisms involving the interactions between polynuclear neutrophils and the vessel wall, and microglial activation. Fenofibrate modulates mechanisms involved in neurorepair and amyloid cascade. Our results suggest that PPAR-α agonists could check the key points of a potential disease-modifying effect in stroke.

摘要

在中风中,迫切需要开发能够(1)诱导神经保护和血管保护,(2)调节恢复和大脑可塑性,以及(3)限制短期运动和认知后果的疾病修饰药物。我们假设,非诺贝特,一种过氧化物酶体增殖物激活受体-α(PPAR-α)激动剂,可能通过其多效机制对中风后即刻和短期相关的后果产生有益影响。大鼠或小鼠接受局灶性缺血,以确定非诺贝特的急性治疗对(i)运动和记忆障碍,(2)脑和血管区室,(3)炎症,(4)神经发生和(5)淀粉样蛋白级联的影响。我们表明,非诺贝特的给药导致神经元和血管保护,并通过与几种机制的相互作用来预防中风后的短期运动和认知后果。PPAR-α的调节通过涉及多形核中性粒细胞和血管壁以及小胶质细胞激活之间相互作用的机制产生即刻中风后果的有益效果。非诺贝特调节涉及神经修复和淀粉样蛋白级联的机制。我们的结果表明,PPAR-α激动剂可以检查中风中潜在疾病修饰作用的关键点。